Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Loqtorzi is a prescription programmed death receptor-1 blocking monoclonal antibody containing toripalimab-tpzi. It is indicated with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. It is also indicated alone for recurrent unresectable or metastatic nasopharyngeal carcinoma after progression on or after platinum-containing chemotherapy.
read more about loqtorzi ...Toripalimab-tpzi binds to the PD-1 receptor on immune cells and prevents its interaction with PD-L1 and PD-L2. Blocking this inhibitory pathway increases T-cell immune activity against susceptible tumor cells.
Loqtorzi is used in adults with qualifying metastatic or recurrent nasopharyngeal carcinoma. First-line treatment combines Loqtorzi with cisplatin and gemcitabine. Patients with recurrent unresectable or metastatic disease that progresses during or after platinum-containing chemotherapy can receive Loqtorzi alone. Pediatric safety and efficacy are not established.
First-line combination treatment uses 240 mg intravenously every three weeks until disease progression, unacceptable toxicity, or a maximum of 24 months. Single-agent treatment uses 3 mg per kg intravenously every two weeks until progression or unacceptable toxicity. The first infusion lasts at least 60 minutes. Later infusions can be given over 30 minutes when the first infusion causes no infusion-related reaction.
Loqtorzi can cause severe or fatal immune-mediated reactions affecting the lungs, intestines, liver, endocrine glands, kidneys, skin, and other organs. Other serious concerns include infusion-related reactions, complications of allogeneic stem cell transplantation, and fetal harm. Liver enzymes, kidney function, and thyroid function are monitored during treatment.
Loqtorzi treats selected metastatic or recurrent nasopharyngeal carcinoma in adults.
The first-line dose is 240 mg intravenously every three weeks with cisplatin and gemcitabine.
The recommended single-agent dose is 3 mg per kg intravenously every two weeks.
Yes. Serious immune-mediated reactions can affect multiple organs and sometimes become fatal.
DailyMed - LOQTORZI (toripalimab-tpzi) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82e7921a-1e84-4988-9799-0ad7d19b2a75. Date Accessed October 13, 2026.
LOQTORZI (toripalimab-tpzi) Prescribing Information. Coherus Oncology. https://loqtorzi.com/pdf/prescribing-information.pdf. Date Accessed October 13, 2026.
Search Orphan Drug Designations and Approvals - Loqtorzi. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=738620. Date Accessed October 13, 2026.
Toripalimab-tpzi. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/toripalimab-tpzi. Date Accessed October 13, 2026.
Toripalimab-tpzi Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a624004.html. Date Accessed October 13, 2026.